Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) has announced a strategic move to issue shares in settlement of debt, a decision that could significantly impact the company's financial health, liquidity, and strategic direction. The company has negotiated debt settlements with arm's length creditors, including AI4LYF, an innovative smart-health company. By issuing shares to settle debt, Therma Bright aims to improve its balance sheet, preserve cash, and strengthen its partnership with AI4LYF.



The debt settlement involves Therma Bright issuing a total of 5,056,250 common shares at a deemed price of $0.08 per share to settle aggregate debt of $404,500. This issuance reduces Therma Bright's outstanding liabilities, improving its balance sheet and enhancing its liquidity position. By converting debt into equity, the company preserves cash that can be allocated towards other operational expenses or investments, ultimately supporting its growth and strategic initiatives.

AI4LYF's participation in the shares for debt transaction further strengthens Therma Bright's financial position. By accepting shares instead of cash, AI4LYF reduces the overall progress payments due to them, which improves Therma Bright's cash flow and liquidity. Additionally, AI4LYF's confidence in Therma Bright and the potential for the investment over time is reflected in their decision to participate in this transaction, which can boost investor confidence in the company.

The shares for debt issuance also influences Therma Bright's strategic direction by progressing the Company's contractual obligation to AI4LYF, which is the global exclusive license holder of the innovative AI-powered Digital Cough Technology (DCT). This technology is currently being considered as a partner technology for a new, innovative, and disruptive chronic cough drug U.S.-based clinical trial. Additionally, the Company and AI4LYF are pursuing a U.S. Food and Drug Administration (FDA) 513(g) request to obtain information regarding the classification and regulatory requirements for this AI-powered technology to be used as a remote therapeutic monitoring (RTM) solution.

The DCT has the potential to be a significant revenue stream for Therma Bright, as the global respiratory monitoring devices market size is expected to grow from USD $1.50 billion in 2022 to USD $2.99 billion by 2032. By maintaining a strong relationship with AI4LYF and successfully developing and commercializing the DCT, Therma Bright can tap into this growing market and expand its strategic direction.

In conclusion, Therma Bright's shares for debt issuance is a strategic move that improves the company's financial health and liquidity, strengthens its partnership with AI4LYF, and progresses the development and commercialization of the innovative AI-powered Digital Cough Technology. This transaction positions Therma Bright for future growth and success in the expanding respiratory monitoring devices market.